Section · Administrative Rules of South Dakota · View on sdlegislature.gov ↗
Category II reportable diseases and conditions include: (1) Acute flaccid myelitis; (2) Anaplasmosis (Anaplasma phagocytophilum); (3) Arboviral encephalitis, meningitis or infection (Eastern equine, Western equine, California serogroup, St Louis, Japanese, Powassan, West Nile virus, Chikungunya, Colorado tick fever, Zika virus); (4) Babesiosis (Babesia spp); (5) Campylobacteriosis (Campylobacter spp.); (6) Chancroid (Haemophilus ducreyi); (7) Carbon monoxide poisoning; (8) Chicken pox/Varicella (herpesvirus); (9) Chlamydia infections (Chlamydia trachomatis); (10) Cholera (Vibrio cholerae); (11) Cryptosporidiosis (Cryptosporidium parvum); (12) Coccidioidomycosis (Coccidioides spp); (13) Cyclospora (Cyclospora cayetanensis); (14) Dengue viral infection (flaviviruses); (15) Drug resistant organisms: (a) Vancomycin-resistant Staphylococcus aureus (VRSA); (b) Carbapenemase-producing organisms; (c) Candida auris; (16) Ehrlichiosis (Ehrlichia spp.); (17) Giardiasis (Giardia lamblia); (18) Gonorrhea (Neisseria gonorrhoeae); (19) Haemophilus influenzae, invasive disease; (20) Hantavirus pulmonary syndrome and Hantavirus infection (Hantaviruses); (21) Hemolytic uremic syndrome; (22) Hepatitis, viral types A, B, and C, including all molecular Hepatitis C results; (23) Human immunodeficiency virus (HIV) infection; including: (a) AIDS (Stage III infection); (b) CD4 counts in HIV infection persons; (c) HIV viral loads; (d) Pregnancy in HIV-infected females; (e) HIV gene sequencing; (f) HIV antiviral resistance; and (g) Confirmatory results, positive or negative, following a reactive HIV screening test; (24) Influenza: (a) Laboratory-confirmed cases; (b) Influenza-associated deaths; (c) Influenza-associated hospitalizations; and (d) Weekly reports of number of rapid antigen influenza positive tests and total number tested; (25) Lead, all blood levels; (26) Legionellosis (Legionella spp.); (27) Leprosy/Hansen's disease (Mycobacterium leprae); (28) Leptospirosis (Leptospira); (29) Listeriosis (Listeria monocytogenes); (30) Lyme disease (Borrelia burgdorferi); (31) Malaria (Plasmodium spp.); (32) Melioidosis (Burkholderia pseudomallei); (33) Mumps; (34) Pertussis (Bordetella pertussis); (35) Pesticide-related illness and injury, acute; (36) Psittacosis (Chlamydia psittaci); (37) Q fever (Coxiella burnetii); (38) Salmonellosis (Salmonella spp.); (39) Shigellosis (Shigella spp.); (40) Silicosis; (41) Spotted Fever Rickettsiosis (Rickettsia spp); (42) Streptococcus pneumoniae, invasive; (43) Syphilis (Treponema pallidum), including primary, secondary, early latent, late latent, neurosyphilis, ocular syphilis, otosyphilis, stillbirth, and congenital; (44) Tetanus (Clostridium tetani); (45) Toxic shock syndrome (Streptococcal and non-Streptococcal); (46) Transmissible spongiform encephalopathies, such as Creutzfeldt-Jakob disease; (47) Trichinosis (Trichinella spiralis); (48) Tuberculosis (Mycobacterium tuberculosis or Mycobacterium bovis): Latent infection in a high risk person; (49) Typhoid (Salmonella typhi); and (50) Vibriosis (Vibrionaceae).
Source: 20 SDR 69, effective November 17, 1993; 23 SDR 60, effective October 31, 1996; 28 SDR 92, effective December 30, 2001; 29 SDR 87, effective December 22, 2002; 30 SDR 87, effective December 7, 2003; 31 SDR 89, effective December 27, 2004; 33 SDR 106, effective December 26, 2006; 34 SDR 179, effective December 24, 2007; 38 SDR 8, effective August 1, 2011; 39 SDR 203, effective June 10, 2013; 42 SDR 77, effective November 30, 2015; 42 SDR 173, effective July 1, 2016; 45 SDR 83, effective December 17, 2018; 50 SDR 12, effective August 8, 2023.